- Home
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Club
- Mobile
- Trust Equitymaster
- Help
- Free Reports
-
Mobile App
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - pharmaceuticals
- ASTRAZENECA PHARMA - MYLAN (US)
ASTRAZENECA PHARMA vs MYLAN (US) - Comparison Results
ASTRAZENECA PHARMA 
Change
AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 ASTRAZENECA PHARMA  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ASTRAZENECA PHARMA Mar-14 |
MYLAN Dec-14 |
ASTRAZENECA PHARMA/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,285 | 3,862 | - | |
| Low | Rs | 634 | 2,722 | - | |
| Sales per share (Unadj.) | Rs | 189.6 | 1,322.1 | - | |
| Earnings per share (Unadj.) | Rs | -0.2 | 159.3 | - | |
| Cash flow per share (Unadj.) | Rs | 3.8 | 256.4 | - | |
| Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
| Dividend yield (eoy) | % | 0 | 0 | - | |
| Book value per share (Unadj.) | Rs | 68.6 | 657.2 | - | |
| Shares outstanding (eoy) | m | 25.00 | 378.37 | - | |
| Bonus/Rights/Conversions | - | OI | - | ||
| Price / Sales ratio | x | 5.1 | 2.5 | 203.3% | |
| Avg P/E ratio | x | -4,712.7 | 20.7 | -22,801.8% | |
| P/CF ratio (eoy) | x | 249.6 | 12.8 | 1,943.8% | |
| Price / Book Value ratio | x | 14.0 | 5.0 | 279.1% | |
| Dividend payout | % | 0 | 0 | - | |
| Avg Mkt Cap | Rs m | 23,988 | 1,245,533 | 1.9% | |
| No. of employees | `000 | 1.6 | 25.0 | 6.2% | |
| Total wages/salary | Rs m | 1,605 | 0 | - | |
| Avg. sales/employee | Rs Th | 3,040.2 | 20,010.2 | 15.2% | |
| Avg. wages/employee | Rs Th | 1,029.2 | 0 | - | |
| Avg. net profit/employee | Rs Th | -3.3 | 2,410.6 | -0.1% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 4,740 | 500,256 | 0.9% | |
| Other income | Rs m | 92 | -2,916 | -3.2% | |
| Total revenues | Rs m | 4,832 | 497,340 | 1.0% | |
| Gross profit | Rs m | -130 | 124,416 | -0.1% | |
| Depreciation | Rs m | 101 | 36,742 | 0.3% | |
| Interest | Rs m | 0 | 21,578 | 0.0% | |
| Profit before tax | Rs m | -139 | 63,180 | -0.2% | |
| Minority Interest | Rs m | 0 | -259 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 139 | 0 | - | |
| Tax | Rs m | 5 | 2,657 | 0.2% | |
| Profit after tax | Rs m | -5 | 60,264 | -0.0% | |
| Gross profit margin | % | -2.7 | 24.9 | -11.0% | |
| Effective tax rate | % | -3.7 | 4.2 | -87.1% | |
| Net profit margin | % | -0.1 | 12.0 | -0.9% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 2,726 | 439,791 | 0.6% | |
| Current liabilities | Rs m | 2,435 | 343,829 | 0.7% | |
| Net working cap to sales | % | 6.1 | 19.2 | 32.1% | |
| Current ratio | x | 1.1 | 1.3 | 87.5% | |
| Inventory Days | Days | 74 | 78 | 94.5% | |
| Debtors Days | Days | 41 | 107 | 38.0% | |
| Net fixed assets | Rs m | 1,035 | 115,733 | 0.9% | |
| Share capital | Rs m | 50 | 17,690 | 0.3% | |
| Net worth | Rs m | 1,716 | 248,676 | 0.7% | |
| Long term debt | Rs m | 0 | 371,498 | 0.0% | |
| Total assets | Rs m | 4,156 | 1,001,646 | 0.4% | |
| Interest coverage | x | NM | 3.9 | - | |
| Debt to equity ratio | x | 0 | 1.5 | 0.0% | |
| Sales to assets ratio | x | 1.1 | 0.5 | 228.3% | |
| Return on assets | % | -0.1 | 8.2 | -1.5% | |
| Return on equity | % | -0.3 | 24.2 | -1.2% | |
| Return on capital | % | 0 | 13.6 | 0.0% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | -8 | 65,759 | -0.0% | |
| From Investments | Rs m | -146 | -51,859 | 0.3% | |
| From Financial Activity | Rs m | 862 | -17,328 | -5.0% | |
| Net Cashflow | Rs m | 709 | -3,428 | -20.7% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.8 Rs / USD
Compare ASTRAZENECA PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare ASTRAZENECA PHARMA With: ABBOTT INDIA FDC LTD. BIOCON LTD IPCA LABS PANACEA BIOTECH
|
| |
Today's Market
Global Markets Steady Despite North Korea Threat(RoundUp)
Global financial markets ended the week on a flat note despite North Korea once again threatening to test a hydrogen bomb in the Pacific Ocean.
Related Views On News
Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)
Sep 22, 2017Muted growth in CRAMS segment continues to impact topline.
Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)
Aug 14, 2017A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)
Aug 14, 2017GST impact coupled with price erosion in US leads to lower profits for the quarter.
Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)
Aug 8, 2017Profits plunge due to higher raw material costs.
Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)
Jun 23, 2017Net Profit lower due to exceptional items in the previous year.
More Views on NewsMost Popular
India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)
Sep 11, 2017The question is, whether real estate buyers are financial creditors or not.
Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)
Sep 13, 2017Nifty is above 10,000 once again. Have you missed the bus?
Rule-Based Investing Can Make A Lot of Money(The 5 Minute Wrapup)
Sep 16, 2017We take a glimpse of Equitymaster's results from rule based investing.
Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments
Sep 18, 2017Welcome to a bold, new initiative designed for the truly contrarian investor.
How To Link Aadhaar With Your Mutual Fund Investments(Outside View)
Sep 11, 2017The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.
More|
| |
ASTRAZENECA PHARMA SHARE PRICE
Sep 22, 2017 (Close)
TRACK ASTRAZENECA PHARMA
- Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ASTRAZENECA PHARMA
ASTRAZENECA PHARMA 5-YR ANALYSIS
COMPARE ASTRAZENECA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | Advertise | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
